These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32857769)

  • 1. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.
    Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto K; Hasegawa H; Takei Y
    PLoS One; 2020; 15(8):e0237370. PubMed ID: 32857769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels.
    Nakayama A; Fukuda H; Ebara M; Hamasaki H; Nakajima K; Sakurai H
    Biol Pharm Bull; 2002 Apr; 25(4):426-31. PubMed ID: 11995918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma.
    Ebara M; Fukuda H; Hatano R; Saisho H; Nagato Y; Suzuki K; Nakajima K; Yukawa M; Kondo F; Nakayama A; Sakurai H
    J Hepatol; 2000 Sep; 33(3):415-22. PubMed ID: 11019997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort.
    Fang AP; Chen PY; Wang XY; Liu ZY; Zhang DM; Luo Y; Liao GC; Long JA; Zhong RH; Zhou ZG; Xu YJ; Xu XJ; Ling WH; Chen MS; Zhang YJ; Zhu HL
    Int J Cancer; 2019 Jun; 144(11):2823-2832. PubMed ID: 30426509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of distribution patterns for copper and zinc in metallothionein and superoxide dismutase in chronic liver diseases and hepatocellular carcinoma using high-performance liquid chromatography (HPLC).
    Kubo S; Fukuda H; Ebara M; Ikota N; Saisho H; Nakagawa H; Ozawa T; Yukawa M; Kato K; Satoh T; Watayo T; Sakurai H
    Biol Pharm Bull; 2005 Jul; 28(7):1137-41. PubMed ID: 15997086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
    Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors.
    Franck M; Schütte K; Malfertheiner P; Link A
    World J Gastroenterol; 2020 Jan; 26(1):86-96. PubMed ID: 31933516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallothionein 2A expression and its relation to different clinical stages and grades of breast cancer in Egyptian patients.
    Rezk NA; Zidan HE; Riad M; Mansy W; Mohamad SA
    Gene; 2015 Oct; 571(1):17-22. PubMed ID: 26093198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
    Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
    Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
    Hayashi T; Shibata M; Oe S; Miyagawa K; Honma Y; Harada M
    PLoS One; 2020; 15(12):e0244370. PubMed ID: 33351844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
    Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved diagnostic method for chronic hepatic disorder: analyses of metallothionein isoforms and trace metals in the liver of patients with hepatocellular carcinoma as determined by capillary zone electrophoresis and inductively coupled plasma-mass spectrometry.
    Kawata T; Nakamura S; Nakayama A; Fukuda H; Ebara M; Nagamine T; Minami T; Sakurai H
    Biol Pharm Bull; 2006 Mar; 29(3):403-9. PubMed ID: 16508136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of Copper in Hepatocarcinogenesis via the Activation of Hypoxia-Inducible Factor-1α.
    Himoto T; Fujita K; Nomura T; Tani J; Miyoshi H; Morishita A; Yoneyama H; Kubota S; Haba R; Suzuki Y; Masaki T
    Biol Trace Elem Res; 2016 Nov; 174(1):58-64. PubMed ID: 27121973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
    Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
    PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma.
    Chen X; Liu H; Pan D; Yao Z; Han Z; Qu P
    Technol Cancer Res Treat; 2024; 23():15330338241277695. PubMed ID: 39263703
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
    Wang DX; Yang X; Lin JZ; Bai Y; Long JY; Yang XB; Seery S; Zhao HT
    World J Gastroenterol; 2020 Aug; 26(30):4465-4478. PubMed ID: 32874058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.